Metraipolis › archive › dc_50af5012aece

Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study — Europe PMC PMID:42130618

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42130618
DOI
10.3389/fonc.2026.1796804
License (as archived)
solo-consultazione
Archived
2026-11-03T04:03:56.616Z
SHA-256 of the archived text
232a4ff6644a5c645f8b7b813aa0e0efbbf2c902dd9d0a48fb4430ea91b81164
Stable URL of this page
https://metraipolis.com/documento/dc_50af5012aece

How to cite

Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study — Europe PMC PMID:42130618 — Europe PMC (en), https://europepmc.org/article/MED/42130618 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_50af5012aece (Metraipolis archive dc_50af5012aece, sha256 232a4ff6644a5c645f8b7b813aa0e0efbbf2c902dd9d0a48fb4430ea91b81164)
BibTeX
@misc{dc50af5012aece,
  title = {Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study — Europe PMC PMID:42130618},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42130618},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_50af5012aece; sha256 232a4ff6644a5c645f8b7b813aa0e0efbbf2c902dd9d0a48fb4430ea91b81164},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42130618. Agents can read the archived copy with the MCP tool read_document.